ESH 2017 | Therapeutics targeting splicing in hematological malignancies

Currently, the majority of therapeutics that target splicing mutations in hematological malignancies are in the early or pre-clinical phases. In this video, Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses one such exciting trial, NCT02841540. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).